Abstract Library

#4570 Diagnosis of carcinoid heart disease continues to be late delayed

Introduction: Carcinoid heart disease (CHD) is a serious complication of neuroendocrine tumours. It affects patients with carcinoid syndrome and results from fibrotic deposits on the heart valves. It significantly impacts patient prognosis.

Conference:

Presenting Author:

Authors: Sharma J, Shah T, Coldham C, Vickrage S, Rehman Z,

Keywords: carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, symptoms, presentation, echocardiogram, heart valves,

#4544 Spatial and temporal intratumour heterogeneity of pancreatic neuroendocrine tumours (PanNET)

Introduction: Data derived from the study of intertumour heterogeneity have led to propose that PanNET evolution may start either from beta cells with good prognosis, or from alpha cells with sequential alterations of MDA (MENIN-DAXX/ATRX) leading to more aggressive lesions.

Conference:

Presenting Author: Awan Z

Authors: Awan Z, Bourdeleau P, Epée J, Ps H, Tihy M,

Keywords: Pancreatic neuroendocrine tumour, Heterogeneity, Tumour microenvironment,

#4092 Liver transplantation for neuroendocrine tumor liver metastases: UK and Ireland’s pioneering pilot programme

Introduction: The incidence of neuroendocrine tumours (NETs) continues to rise. Liver metastases (LM) are commonly present at diagnosis. Liver transplantation (LT) has become an applicable treatment for a subset of these patients.

Conference:

Presenting Author: Rehman Z

Authors: Rehman Z, Ford S, Dasari B, Hughes S, El-Shafie M,

Keywords: metastases, transplant, liver, neuroendocrine,

#4089 Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,

Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,

#4051 TECANT ERA PerMed study – Somatostatin receptor antagonists as a new sensitive diagnostic tool for reliable assessment of the SSTR status in neuroendocrine neoplasms

Introduction: The radiolabelled somatostatin receptors (SSTR) agonist development was a milestone in the management of neuroendocrine tumors (NEN), however the SSTR antagonist recognize more binding sites on NEN cells which should improve the diagnostic efficacy. The development of technetium-99m based radiopharmaceuticals should improve access to this clinically feasible diagnostic tool.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Virgolini I, Lezaic L, Decristoforo C, Kolenc P,

Keywords: NET, SSTR antagonist, SPECT/CT, SSTR, TECANT, [99mTc]Tc-TECANT1,